Skip to main content

Advertisement

SpringerLink
Log in

Oral Contraceptive Use and Bone

  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Sex hormones play a key role in bone homeostasis, and oral contraceptive (OC) use may affect bone mass in women. However, the nature of the association between OC use and bone remains controversial. This paper critically reviews studies on OC use and bone published between January 2009 and August 2010. Studies of OC use and bone mass mainly focus on adolescents or young adults and showed mixed results. Weak evidence suggests that OC use has no effect or a beneficial effect on bone mass, except in women commencing OCs shortly after menarche, and a consistently negative effect on bone turnover markers. A limited number of studies have examined the effect of ultra-low-dose OC (20 μg ethinyl estradiol) on bone mass in adolescents or young adults, and present conflicting results. The lack of randomized trials indicates that further high-quality prospective studies are required to investigate the effect of OC use on bone mass, particularly the optimal dose and timing of initiation of OC use in adolescents requiring contraception.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Caliri A, De Filippis L, Bagnato GL, Bagnato GF: Osteoporotic fractures: mortality and quality of life. Panminerva Med 2007, 49:21–27.

    CAS  PubMed  Google Scholar 

  2. Riggs BL, Khosla S, Melton LJ 3rd: Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002, 23:279–302.

    Article  CAS  PubMed  Google Scholar 

  3. Greenwald MW, Gluck OS, Lang E, Rakov V: Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. Menopause 2005, 12:741–748.

    Article  PubMed  Google Scholar 

  4. Heikkinen J, Vaheri R, Haapalahti J, Timonen U: A 10-year follow-up of the effect of continuous-combined hormone replacement therapy and its discontinuation on bone in postmenopausal women. Menopause Int 2008, 14:70–77.

    Article  PubMed  Google Scholar 

  5. Komulainen MH, Kroger H, Tuppurainen MT, et al.: HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas 2008, 61:85–94.

    Article  PubMed  Google Scholar 

  6. Martins SL, Curtis KM, Glasier AF: Combined hormonal contraception and bone health: a systematic review. Contraception 2006, 73:445–469.

    Article  CAS  PubMed  Google Scholar 

  7. Lopez LM, Grimes DA, Schulz KF, Curtis KM: Steroidal contraceptives: effect on bone fractures in women. Cochrane Database Syst Rev 2009, CD006033.

  8. • Wei S, Venn A, Jones G: The association between oral contraceptive use, bone mass and fractures in both young and older women. Presented at the ANZBMS 20th ANNUAL SCIENTIFIC MEETING. Adelaide, Australia; September 6–8, 2010. 2010. This study described the associations between OC use, bone mass, and fractures in two population-based samples of both young and older women.

  9. Meier C, Brauchli YB, Jick SS, et al.: Use of Depot Medroxyprogesterone Acetate and Fracture Risk. J Clin Endocrinol Metab 2010, 5:4909–4916.

    Google Scholar 

  10. •• Lattakova M, Borovsky M, Payer J, Killinger Z: Oral contraception usage in relation to bone mineral density and bone turnover in adolescent girls. Eur J Contracept Reprod Health Care 2009, 14:207–214. This paper compared the effect of a low-dose OC with an ultra-low-dose OC on bone density and bone turnover in healthy adolescents who had no previous use of hormonal contraceptives and were randomized to different OC formulations.

    Article  CAS  PubMed  Google Scholar 

  11. • Beksinska ME, Kleinschmidt I, Smit JA, Farley TM: Bone mineral density in a cohort of adolescents during use of norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives and after discontinuation of norethisterone enanthate. Contraception 2009, 79:345–349. This is one of the few prospective studies to examine the effect of low-dose OC on BMD in adolescents who had no previous use of hormonal contraceptive.

    Article  CAS  PubMed  Google Scholar 

  12. •• Scholes D, Ichikawa L, LaCroix AZ, et al.: Oral contraceptive use and bone density in adolescent and young adult women. Contraception 2010, 81:35–40. This study investigated the association between duration of OC use and BMD in both adolescents and young adults, and also examined different dosages of OC in a population-based sample.

    Article  CAS  PubMed  Google Scholar 

  13. Holmes BL, Ludwa IA, Gammage KL, et al.: Relative importance of body composition, osteoporosis-related behaviors, and parental income on bone speed of sound in adolescent females. Osteoporos Int 2010, 21:1953–1957.

    Article  CAS  PubMed  Google Scholar 

  14. • Wei S, Jones G, Thomson R, et al.: Oral contraceptive use and bone mass in women aged 26–36 years. Osteoporos Int 2011, in press. This study investigated the association between OC use and bone mass in a large population-based young adult sample with careful adjustment for confounders.

  15. Chan R, Woo J, Lau W, et al.: Effects of lifestyle and diet on bone health in young adult Chinese women living in Hong Kong and Beijing. Food Nutr Bull 2009, 30:370–378.

    PubMed  Google Scholar 

  16. Beksinska ME, Kleinschmidt I, Smit JA, et al.: Bone mineral density in young women aged 19–24 after 4–5 years of exclusive and mixed use of hormonal contraception. Contraception 2009, 80:128–132.

    Article  CAS  PubMed  Google Scholar 

  17. Allali F, El Mansouri L, Abourazzak F, et al.: The effect of past use of oral contraceptive on bone mineral density, bone biochemical markers and muscle strength in healthy pre and post menopausal women. BMC Womens Health 2009, 9:31.

    Google Scholar 

  18. Sarfati J, de Vernejoul MC: Impact of combined and progestogen-only contraceptives on bone mineral density. Joint Bone Spine 2009, 76:134–138.

    Article  PubMed  Google Scholar 

  19. Pikkarainen E, Lehtonen-Veromaa M, Mottonen T, et al.: Estrogen-progestin contraceptive use during adolescence prevents bone mass acquisition: a 4-year follow-up study. Contraception 2008, 78:226–231.

    Article  CAS  PubMed  Google Scholar 

  20. Hartard M, Kleinmond C, Wiseman M, et al.: Detrimental effect of oral contraceptives on parameters of bone mass and geometry in a cohort of 248 young women. Bone 2007, 40:444–450.

    Article  CAS  PubMed  Google Scholar 

  21. Palep-Singh M, Prentice A: Epidemiology of abnormal uterine bleeding. Best Pract Res Clin Obstet Gynaecol 2007, 21:887–890.

    Article  PubMed  Google Scholar 

  22. Agostino H, Di Meglio G: Low-dose Oral Contraceptives in Adolescents: How Low Can You Go? J Pediatr Adolesc Gynecol 2010, 23:195–201.

    Article  CAS  PubMed  Google Scholar 

  23. Seibel MJ: Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis. Clin Biochem Rev 2006, 27:123–138.

    PubMed  Google Scholar 

  24. Delmas PD, Eastell R, Garnero P, et al.: The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000, 11(Suppl 6):S2–17.

    Article  PubMed  Google Scholar 

  25. Herrmann M, Seibel MJ: The effects of hormonal contraceptives on bone turnover markers and bone health. Clin Endocrinol (Oxf) 2010, 72:571–583.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This research and salaries for G. Jones and T. Winzenberg are supported in part by the National Health and Medical Research Council of Australia.

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Menzies Research Institute, University of Tasmania, Private bag 23, Hobart, Tasmania, 7000, Australia

    Shuying Wei, Tania Winzenberg, Laura L. Laslett, Alison Venn & Graeme Jones

Authors
  1. Shuying Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tania Winzenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laura L. Laslett
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alison Venn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Graeme Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shuying Wei.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wei, S., Winzenberg, T., Laslett, L.L. et al. Oral Contraceptive Use and Bone. Curr Osteoporos Rep 9, 6–11 (2011). https://doi.org/10.1007/s11914-010-0037-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-010-0037-9

Keywords

Search

Navigation